American Journal of Biomedical and Life Sciences
Volume 7, Issue 6, December 2019, Pages: 155-158
Received: Sep. 20, 2019;
Accepted: Nov. 6, 2019;
Published: Dec. 2, 2019
Views 347 Downloads 112
Edna Kurgat, Department Public Health, South Eastern Kenya University, Nairobi, Kenya
Doaa Ghareeb, Department Public Health, South Eastern Kenya University, Nairobi, Kenya
As total life expectancy increases, the prevalence of age-related diseases such as Alzheimer’s is also increasing. Many hypotheses about Alzheimer’s disease have been developed, including cholinergic neuron damage. Acetylcholine is a major neurotransmitter in the brain and cholinergic deficits leads to cognitive dysfunction and decline. Despite decades of research and advances in our understanding of its aetiology and pathogenesis, current pharmacotherapeutic options for AD are still very limited and represent an area of need that is currently unmet. In abnormal activation of AChE, acetylcholine will degrade rapidly, especially in the brain and this is associated with Alzheimer’s disease (AD). It has been shown that theraphy with essential oils from medicinal plants can improve cognitive performance in Alzheimer’s disease patients. Eugenol from these essential oils is reported to inhibit acetylcholinesterase, both in vitro and in vivo. This paper is set to Determine inhibitory/stimulatory effect of tested extracts on acetylcholine esterase (AChE) activity. The sampled out plant extracts include Thymus vulgaris, Berberis vulgaris and Calluna vulgaris with which inhibition or activation by different chemical catalysts is performed to establish their effects in the tested natural extracts. Experimental design is used where the reagents are determined and chemical reactions performed in the procedures as outlined in the methodology section. The results of the cholinergic/ anti-cholinergic effect of tested natural extracts are then recorded. This study reflects that most of the extracts inhibited AChE activity with berberis vulgaris showing highest inhibitory effect.
Bioactive Compounds and Essential Oils as Acetylcholinesterase Inhibitors, American Journal of Biomedical and Life Sciences.
Vol. 7, No. 6,
2019, pp. 155-158.
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/
) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
M. Ayaz, Sadiq A, Junaid M, Ullah F, Subhan F, Ahmed J. Neuroprotective and anti-aging potentials of essential oils from aromatic and medicinal plants. Front Aging Neurosci. 2017; 9: 168.
K. Wollen, A. Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern. Med. Rev. 2010; 15 (3): 223–24.
D .Ghareeb, Newaairy A, El-rashidy F, Hussein H, Ali A (2010). Efficacy of natural extracts of Ginko biloba and Berberry and synthrtic derivative of genistein as acethylcholinestarase inhibitors, comparative study with Aricept effect. J. Biochem. Biotechnol. 1: 15-20.
K. Yoo, Hwang IK, Lim BO, Kang TC, Kim D W.et al (2006). Berberry Extract Reduces Neuronal Damage and N-Methyl-D-aspartate Receptor 1 Immuno reactivity in the Gerbil hippocampus after Transient Fore brain Ischemia. Biol. Pharm. Bull. 29 (4): 623-628.
S. Dandle, Miguel MG, Duarte J, Faleiro ML, Sousa MJ, Lima AS, FigueiredoAC, Barroso JG, Pedro LG (2011).Acetyl cholinesterase inhibition activity of Portuguese Thymus species essential oils. J. Essent. Oil Bear. Pl., 14: 140-150.
M. Asai. NI wata, A. Yoshikawa.,Y. Aizaki, S. Ishiura, T. Saido and Maruyama, K. (2007) Berberine alters the processing of Alzheimer’s amyloid precursor 152 protein to decrease Abeta secretion. Biochem. Biophys. Res. Commun. 352 (2) 498-502.
P. Williams, Sorribas A, Howes MJ. Natural Products as a source of Alzheimer’s drugs leads. Nat. Prod. Rep. . 2011; 28: 48–77.
G. Ellman .,Courtney K.D., Andres VJr, Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961; 7: 88–95.
Houghton PJ, Y Ren, MJ Howes. Acetylcholinesterase inhibitors from plants and fungi. Nat. Prod. Rep. 23 (2006): 181-199. 13.
Williams P, A Sorribas, MJ Howes. Natural Products as a source of Alzheimer’s drugs leads. Nat. Prod. Rep. 28 (2011): 48-77. 14.
Mukherjee PK, V Kumar, M Mal, PJ Houghton. Acetylcholinesterase inhibitors from plants. Phytomedicine 14 (2007): 289-300. 15.
Orhan G, I Orhan, N Subutay-Oztekin, F Ak, B Sener. Contemporary anticholinesterase pharmaceuticals of natural origin and their synthetic analogues for the treatment of Alzheimer's disease. Recent. Pat. CNS Drug. Discov. 4 (2009): 43-51.
Rounsaville TJ, Ranney TG. Ploidy levels and genome sizes of Berberis L. and Mahonia nutt. species, hybrids, and cultivars. Hortscience. 2010; 45: 1029–33.
Tomosaka H, Chin YW, Salim AA, Keller WJ, Chai H, Kinghorn AD. Antioxidant and cytoprotective compounds from Berberis vulgaris (Barberry) Phytother Res. 2008; 22: 979–81.
Saied S, Begum S. Phytochemical studies of Berberis vulgaris. Chem Nat Compd. 2004; 40: 137–40.